SEC Form 4 · accession 0000899866-16-000248
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carsten Thiel
Officer — EVP, Chief Commercial Officer
Period of report
Feb 4, 2016
Accepted (ET)
Feb 8, 2016 · 7:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Feb 4, 2016 | A | 8,802 | $0.00 | A | 36,820 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On February 4, 2016, the Leadership and Compensation Committee determined that the reporting person earned 8,802 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 4, 2016 and 1/3 vest on each subsequent anniversary.